Differential transendothelial transport of adiponectin complexes

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Rutkowski, Joseph M ^a   Halberg, Nils ^a   Wang, Qiong A ^a   Holland, William L ^a   Xia, Jonathan Y ^a   Scherer, Philipp E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adiponectin; Ceramide; Endothelium; Exercise; Oligomerization

Indexed keywords

ADIPONECTIN; ANIMALS; CAPILLARY PERMEABILITY; CELL LINE; ENDOTHELIAL CELLS; HEK293 CELLS; HUMANS; MALE; MICE; PROTEIN TRANSPORT;

EID: 84894380618     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-47     Document Type: Article

References (52)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270(45):26746-26749. 10.1074/jbc.270.45.26746, 7592907.
2. Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 2008, 149(5):2270-2282. 10.1210/en.2007-1561, 2329278, 18202126.
3. Hamilton MP, Gore MO, Ayers CR, Xinyu W, McGuire DK, Scherer PE. Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diab Vasc Dis Res 2011, 8(3):190-194. 10.1177/1479164111407784, 21555334.
4. Lo MM, Salisbury S, Scherer PE, Furth SL, Warady BA, Mitsnefes MM. Serum adiponectin complexes and cardiovascular risk in children with chronic kidney disease. Pediatr Nephrol 2011, 26(11):2009-2017. 10.1007/s00467-011-1906-x, 3366590, 21553321.
5. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin, implications fpr metabolic regulation and bioactivity. J Biol Chem 2003, 278(11):9073-9085. 10.1074/jbc.M207198200, 12496257.
6. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279(13):12152-12162.
7. Aird WC. Phenotypic heterogeneity of the endothelium: II, Representative vascular beds. Circ Res 2007, 100(2):174-190. 10.1161/01.RES.0000255690.03436.ae, 17272819.
8. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007, 100(2):158-173. 10.1161/01.RES.0000255691.76142.4a, 17272818.
9. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006, 86(1):279-367. 10.1152/physrev.00012.2005, 16371600.
10. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A 2001, 98(11):6390-6395. 10.1073/pnas.101564798, 33478, 11344271.
11. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007, 558(1-3):7-13.
12. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006, 290(2):H560-H576.
13. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 2009, 276(20):5738-5746. 2896500, 19754873.
14. St-Pierre P, Bouffard L, Papirakis ME, Maheux P. Increased extravasation of macromolecules in skeletal muscles of the Zucker rat model. Obesity (Silver Spring) 2006, 14(5):787-793. 10.1038/oby.2006.91, 16855187.
15. Wang H, Liu Z, Li G, Barrett EJ. The vascular endothelial cell mediates insulin transport into skeletal muscle. Am J Physiol Endocrinol Metab 2006, 291(2):E323-E332. 10.1152/ajpendo.00047.2006, 16569759.
16. Raines SM, Richards OC, Schneider LR, Schueler KL, Rabaglia ME, Oler AT, Stapleton DS, Genove G, Dawson JA, Betsholtz C, Attie AD. Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity. Am J Physiol Endocrinol Metab 2011, 301(3):E517-E526. 10.1152/ajpendo.00241.2011, 3174531, 21673305.
17. Wang H, Wang AX, Barrett EJ. Caveolin-1 is required for vascular endothelial insulin uptake. Am J Physiol Endocrinol Metab 2011, 300(1):E134-E144. 10.1152/ajpendo.00498.2010, 3023210, 20959538.
18. Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-Phelps K, Scherer PE. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 2009, 58(9):1961-1970. 10.2337/db08-1750, 2731534, 19581422.
19. Rutkowski JM, Scherer PE. Isolation and quantitation of adiponectin higher order complexes. Methods Enzymol 2014, 537:243-259.
20. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab 2012, 15(2):171-185. 10.1016/j.cmet.2012.01.004, 3278712, 22326219.
21. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999, 274(10):6718-6725. 10.1074/jbc.274.10.6718, 10037770.
22. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007, 117(9):2621-2637. 10.1172/JCI31021, 1950456, 17717599.
23. Sejima H, Tominaga K, Egawa T, Ikeda M, Shibuya K, Kameyama N, Yamauchi A, Shuto H, Kataoka Y. Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model. Eur J Pharmacol 2009, 624(1-3):66-70.
24. Sendo T, Kataoka Y, Takeda Y, Furuta W, Oishi R. Nitric oxide protects against contrast media-increased pulmonary vascular permeability in rats. Invest Radiol 2000, 35(8):472-478. 10.1097/00004424-200008000-00003, 10946974.
25. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 2002, 277(42):40091-40098. 10.1074/jbc.M205948200, 12167625.
26. Dixon JB, Raghunathan S, Swartz MA. A tissue-engineered model of the intestinal lacteal for evaluating lipid transport by lymphatics. Biotechnol Bioeng 2009, 103(6):1224-1235. 10.1002/bit.22337, 3132564, 19396808.
27. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011, 121(5):1858-1870. 10.1172/JCI43378, 3083776, 21490391.
28. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009, 30(5):234-239. 10.1016/j.tips.2009.02.004, 19359049.
29. Dobrian AD. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor. Vascul Pharmacol 2006, 45(1):36-45. 10.1016/j.vph.2006.01.017, 16716756.
30. Tang WH, Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes Obes Metab 2007, 9(4):447-454. 10.1111/j.1463-1326.2006.00616.x, 17587386.
31. Liu Y, Sweeney G. Adiponectin action in skeletal muscle. Best Pract Res Clin Endocrinol Metab 2014, 28(1):33-41. 10.1016/j.beem.2013.08.003, 24417944.
32. Kolka CM, Bergman RN. The endothelium in diabetes: its role in insulin access and diabetic complications. Rev Endocr Metab Disord 2013, 14(1):13-19. 10.1007/s11154-012-9233-5, 23306780.
33. Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsater H, Scotney P, Nyqvist D, Samen E, Lu L, Stone-Elander S, Proietto J, Andrikopoulos S, Sjoholm A, Nash A, Eriksson U. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012, 490(7420):426-430. 10.1038/nature11464, 23023133.
34. Miller NE, Michel CC, Nanjee MN, Olszewski WL, Miller IP, Hazell M, Olivecrona G, Sutton P, Humphreys SM, Frayn KN. Secretion of adipokines by human adipose tissue in vivo: partitioning between capillary and lymphatic transport. Am J Physiol Endocrinol Metab 2011, 301(4):E659-E667. 10.1152/ajpendo.00058.2011, 21750269.
35. Plant S, Shand B, Elder P, Scott R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res 2008, 5(2):102-108. 10.3132/dvdr.2008.017, 18537097.
36. Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, Wang E, Lee MJ. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem 2006, 281(39):29190-29200. 10.1074/jbc.M604310200, 16891661.
37. Zhang QJ, Holland WL, Wilson L, Tanner JM, Kearns D, Cahoon JM, Pettey D, Losee J, Duncan B, Gale D, Kowalski CA, Deeter N, Nichols A, Deesing M, Arrant C, Ruan T, Boehme C, McCamey DR, Rou J, Ambal K, Narra KK, Summers SA, Abel ED, Symons JD. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 2012, 61(7):1848-1859. 10.2337/db11-1399, 3379648, 22586587.
38. Krause M, Rodrigues-Krause J, O'Hagan C, De Vito G, Boreham C, Susta D, Newsholme P, Murphy C. Differential Nitric Oxide levels in the blood and skeletal muscle of Type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metabolism 2012, 61(11):1528-1537. 10.1016/j.metabol.2012.05.003, 22683098.
39. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008, 32(Suppl 7):S13-S18.
40. Klein I, Sanchez-Alavez M, Tabarean I, Schaefer J, Holmberg KH, Klaus J, Xia F, Marcondes MC, Dubins JS, Morrison B, Zhukov V, Sanchez-Gonzalez A, Mitsukawa K, Hadcock JR, Bartfai T, Conti B. AdipoR1 and 2 are expressed on warm sensitive neurons of the hypothalamic preoptic area and contribute to central hyperthermic effects of adiponectin. Brain Res 2011, 1423:1-9. 3215583, 22000082.
41. Park S, Kim DS, Kwon DY, Yang HJ. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol 2011, 23(8):687-698. 10.1111/j.1365-2826.2011.02165.x, 21599766.
42. Stark R, Ashley SE, Andrews ZB. AMPK and the neuroendocrine regulation of appetite and energy expenditure. Mol Cell Endocrinol 2013, 366(2):215-223. 10.1016/j.mce.2012.06.012, 22789749.
43. Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci 2013, 7:177. 3791387, 24109426.
44. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol 2012, 165(2):313-327. 10.1111/j.1476-5381.2011.01560.x, 3268187, 21718299.
45. Kusminski CM, McTernan PG, Schraw T, Kos K, O'Hare JP, Ahima R, Kumar S, Scherer PE. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 2007, 50(3):634-642. 10.1007/s00125-006-0577-9, 17242917.
46. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?. Int J Obes (Lond) 2005, 29(Suppl 1):S17-S23.
47. Mansuy-Aubert V, Zhou QL, Xie X, Gong Z, Huang JY, Khan AR, Aubert G, Candelaria K, Thomas S, Shin DJ, Booth S, Baig SM, Bilal A, Hwang D, Zhang H, Lovell-Badge R, Smith SR, Awan FR, Jiang ZY. Imbalance between neutrophil elastase and its inhibitor alpha1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab 2013, 17(4):534-548. 10.1016/j.cmet.2013.03.005, 23562077.
48. Vu V, Bui P, Eguchi M, Xu A, Sweeney G. Globular adiponectin induces LKB1/AMPK-dependent glucose uptake via actin cytoskeleton remodeling. J Mol Endocrinol 2013, 51(1):155-165. 10.1530/JME-13-0059, 23709749.
49. Zhao L, Chai W, Fu Z, Dong Z, Aylor KW, Barrett EJ, Cao W, Liu Z. Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin delivery. Circ Res 2013, 112(9):1263-1271. 10.1161/CIRCRESAHA.111.300388, 23459195.
50. Goto M, Goto A, Morita A, Deura K, Sasaki S, Aiba N, Shimbo T, Terauchi Y, Miyachi M, Noda M, Watanabe S, Saku Cohort Study G Low-molecular-weight adiponectin and high-molecular-weight adiponectin levels in relation to diabetes. Obesity (Silver Spring) 2013, 22(2):401-407. Saku Cohort Study G.
51. Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM. Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol 2013, 12:170. 10.1186/1475-2840-12-170, 24225161.
52. Karaca U, Schram MT, Houben AJ, Muris DM, Stehouwer CD. Microvascular dysfunction as a link between obesity, insulin resistance and hypertension. Diabetes Res Clin Pract 2013, S0168-8227(13):00445-2.